OCI-AML3 Xenograft Model Service for AML

The OCI-AML3 cell line provides a highly characterized and translationally significant in vivo platform for modeling acute myeloid leukemia (AML), enabling rigorous exploration of myeloid oncogenesis and therapeutic sensitivity. As a specialized pre-clinical contract research organization, Alfa Cytology delivers an integrated, high-precision OCI-AML3 Xenograft Model Service designed to provide reproducible, audit-ready datasets that accelerate your AML drug discovery and development pipeline.

Overview of OCI-AML3 Xenograft Model for AML

The OCI-AML3 xenograft model is an established in vivo translational tool widely utilized in hematological oncology research for the study of AML, particularly for investigating specific mutations and leukemic progression. By transplanting human OCI-AML3 myeloblastic cells into highly permissive, immunodeficient mouse hosts, this model effectively reproduces the systemic dissemination, aggressive bone marrow infiltration, and distinct peripheral blood pathophysiological profiles characteristic of progressive human AML.

Biologically, the OCI-AML3 model is highly valued for its stable engraftment parameters and proliferative consistency, offering pre-clinical researchers a reliable experimental window for conducting rigorous pharmacological assessments. The platform preserves key human myeloid molecular features, including lineage-specific surface markers and altered intracellular signaling cascades---such as those involving NPM1 and DNMT3A mutations---which are essential for evaluating the anti-leukemic potency of targeted small-molecule inhibitors, monoclonal antibodies, and combination therapeutic regimens. This model facilitates a comprehensive understanding of leukemic progression dynamics in an in vivo environment, ensuring that therapeutic responses are evaluated with high physiological relevance.

Cell Line Information: OCI-AML3

The OCI-AML3 cell line was established from the peripheral blood of a patient diagnosed with AML at the time of diagnosis. These cells grow as suspension cultures under standard in vitro laboratory parameters, maintaining a consistent myeloblastic phenotype that serves as a robust proxy for modern hematological cancer studies.

Our Services

Workflow of OCI-AML3 Xenograft Model Construction

• Cell Culture & Quality Control: Human OCI-AML3 cells are expanded in vitro using certified nutrient suspension media under optimized growth parameters. STR authentication and mycoplasma clearance verification are completed prior to inoculation to ensure absolute phenotypic identity and biological purity.
• Host Selection & Acclimatization: Standardized, healthy immunodeficient mice (e.g., NSG or NOD/SCID strains to support hematological engraftment) are sourced from validated vendors. The animals undergo a dedicated acclimatization phase to stabilize baseline biological and physiological metrics.
• Precision Inoculation: A calibrated suspension of high-viability OCI-AML3 cells is prepared in a sterile physiological buffer. The cellular suspension is precisely inoculated in vivo into the host cohorts via tail vein intravenous routes to facilitate systemic leukemic distribution.
• Longitudinal Growth Tracking: Following inoculation, disease progression is systematically monitored using FACS to detect human CD45+ cells or specific myeloid markers in peripheral blood. Animal weight, physical clinical indicators, and systemic disease burden are documented routinely.
• Stratification & Dosing: Once peripheral leukemic chimerism reaches a predetermined, statistically optimal range, the mice are randomized into matched experimental cohorts to ensure balanced baseline systemic dimensions before the initiation of customized therapeutic dosing regimens.

Fig 1. OCI-AML3 Xenograft Model Construction Workflow

Case Study - OCI-AML3 Xenograft Model Development

A pre-clinical validation study was conducted using the OCI-AML3 xenograft model to evaluate the therapeutic efficacy of a novel small-molecule inhibitor targeting myeloid cell survival signaling in AML. Following precision intravenous inoculation of human OCI-AML3 cells into immunodeficient mice, the animals exhibited steady, systemic leukemic engraftment and highly predictable disease progression across all study cohorts. Animals in the active treatment group demonstrated a clear, statistically significant reduction in circulating leukemic blasts and prolonged survival times compared to the vehicle control, confirming the model's high sensitivity and predictive reliability for screening targeted AML therapies.

Why Choose Alfa Cytology?

• Oncology Domain Expertise: Specialized knowledge in the cultivation and maintenance of diverse squamous cell carcinoma lineages, providing reliable in vivo platforms for complex AML studies.
• Rigorous Quality Control: Stringent validation at every phase of in vitro and in vivo processing to completely eliminate confounding biological variables.
• Tailored Experimental Design: Flexible study frameworks accommodating custom mouse strain choices, specific dosing routes, and orthotopic or subcutaneous inoculation pathways.
• High-Resolution Deliverables: Every project concludes with a detailed, audit-ready data report providing comprehensive digital caliper metrics and robust statistical validations.

Contact us

Accelerating your AML pipeline requires a pre-clinical partner with the technical proficiency to execute rigorous in vivo workflows flawlessly. If you are looking to advance your novel compound or require specialized pre-clinical testing using our OCI-AML3 platform, please reach out to us today to discuss your project requirements with our expert scientific team.

For research use only. Not intended for any clinical use.